Literature DB >> 1824907

Clinical safety and efficacy of celiprolol.

K D Lamon1.   

Abstract

The management of essential hypertension requires therapeutic selections that are not only effective in reducing diastolic blood pressure but are also tailored to the individual patient, with minimal effect on patient demographics, concurrent illnesses, and cardiovascular risk factors. Celiprolol hydrochloride is a new highly cardioselective vasodilating beta-adrenoceptor antagonist that has been proven effective and safe for the treatment of essential hypertension. It is comparable to other therapies in blood pressure control while demonstrating an excellent safety profile, favorable hemodynamic activity, and minimal effects on other cardiovascular risk factors. Celiprolol may offer the physician a unique therapeutic alternative.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824907     DOI: 10.1016/0002-8703(91)90446-o

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 3.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 4.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

Review 5.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

6.  Celiprolol: A Unique Selective Adrenoceptor Modulator.

Authors:  James J Nawarskas; Angela Cheng-Lai; William H Frishman
Journal:  Cardiol Rev       Date:  2017 Sep/Oct       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.